Figure 1.

Plasma IL-17A level in Behçet’s Disease (BS), systemic lupus erythematosus (SLE) patients, multiple sclerosis patients (MS) and healthy controls (HC). (A): Box indicating IL-17A level in active BD patients (n=45), remission BD stage (n=28), SLE patients (n=20), MS patients (n=12) and in HC (n=40). The control diseases (SLE and MS patients) were in active disease (B): Box plot indicating elevated levels of IL-17A in 12 BD patients studied respectively in active and in remission stages after 8 to 10 months of treatment. The medians are indicated by a line inside each box, the 25^th and 75^th percentiles by the box limits, the lower and upper error bars represent the 10^th and 90^th percentiles, respectively. (*): Comparison between active BD patients and SLE patients, (P=0.0015).